Lenvatinib Plus Drug-eluting Bead Transarterial Chemoembolization With/without Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma Larger Than 7 cm with Major Portal Vein Tumor Thrombosis: a Multicenter Retrospective Cohort Study

Overview

Journal Int J Surg

Specialty General Surgery

Date 2024 Jun 13

PMID 38869974

Authors

Mingyue Cai

Licong Liang

Jian Zhang

Nianping Chen

Wensou Huang

Yongjian Guo

Xiaotao Hong

Liteng Lin

Yaohong Liu

Cao Dan

Haihui Deng

Xiaoguang Liu

Jingwen Zhou

Ye Chen

Huanwei Chen

Kangshun Zhu

Affiliations

Soon will be listed here.

Abstract

Background: The management of hepatocellular carcinoma (HCC) with high tumor burden and major portal vein tumor thrombosis (PVTT) remains a great challenge. The authors aimed to investigate the efficacy and safety of lenvatinib plus drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil and leucovorin (Len+DEB-TACE+HAIC) versus lenvatinib plus DEB-TACE (Len+DEB-TACE) for HCC greater than 7.0 cm accompanied with major PVTT.

Materials And Methods: This multicenter retrospective cohort study evaluated consecutive patients with HCC (> 7.0 cm) and major PVTT who received Len+DEB-TACE+HAIC (Len+DEB-TACE+HAIC group) or Len+DEB-TACE (Len+DEB-TACE group) between July 2019 and June 2021 from eight institutions in China. Objective response rate (ORR), time to progression (TTP), overall survival (OS), and treatment-related adverse events (TRAEs) were compared between the two groups by propensity score matching (PSM).

Results: A total of 205 patients were included. After PSM, 85-paired patients remained in the study cohorts. Patients in the Len+DEB-TACE+HAIC group had higher ORR (61.2% vs. 34.1%, P < 0.001), longer TTP (median, 9.8 vs. 5.9 months, P < 0.001), and prolonged OS (median, 16.7 vs. 12.5 months, P < 0.001) than those in the Len+DEB-TACE group. The ORR and TTP of both intrahepatic tumor (ORR: 64.7% vs. 36.5%, P < 0.001; median TTP: 10.7 vs. 7.0 months, P < 0.001) and PVTT (ORR: 74.1% vs. 47.1%, P < 0.001; median TTP: 17.4 vs. 7.6 months, P < 0.001) were better in the Len+DEB-TACE+HAIC group than the Len+DEB-TACE group. The frequency of grade 3-4 TRAEs in the Len+DEB-TACE+HAIC group were comparable to those in the Len+DEB-TACE group (38.8% vs. 34.1%, P = 0.524).

Conclusion: The addition of HAIC to Len+DEB-TACE significantly improved ORR, TTP, and OS over Len+DEB-TACE with an acceptable safety profile for large HCC with major PVTT.

Citing Articles

Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching....

Zhong S, Zhang F, Zhang H, Hu H, Zeng Q, Li Y J Hepatocell Carcinoma. 2025; 12:445-458.

PMID: 40046292 PMC: 11881770. DOI: 10.2147/JHC.S506457.

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial.

Hong X, Guo Y, Shi W, Zhu K, Liang L, Lin L BMC Cancer. 2025; 25(1):205.

PMID: 39910472 PMC: 11796178. DOI: 10.1186/s12885-025-13605-2.

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study.

Cai H, Chen S, Tang S, Xiao Y, Shi F, Wu Z Cancer Immunol Immunother. 2025; 74(3):88.

PMID: 39891746 PMC: 11787109. DOI: 10.1007/s00262-025-03942-3.

References

Han K, Kim J, Yoon H, Kim E, Gwon D, Ko G . Transcatheter arterial chemoembolization for infiltrative hepatocellular carcinoma: clinical safety and efficacy and factors influencing patient survival. Korean J Radiol. 2014; 15(4):464-71. PMC: 4105809. DOI: 10.3348/kjr.2014.15.4.464. View

Marrero J, Kulik L, Sirlin C, Zhu A, Finn R, Abecassis M . Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2):723-750. DOI: 10.1002/hep.29913. View

Fan W, Zhu B, Yue S, Zheng X, Zou X, Li F . Idarubicin-Loaded DEB-TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score-matching analysis. Cancer Med. 2022; 12(1):61-72. PMC: 9844616. DOI: 10.1002/cam4.4937. View

Liu B, Gao S, Zhu X, Guo J, Zhang X, Chen H . Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol. 2020; 12(6):663-676. PMC: 7341000. DOI: 10.4251/wjgo.v12.i6.663. View

Lu J, Zhang X, Zhong B, Lau W, Madoff D, Davidson J . Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019; 4(9):721-730. DOI: 10.1016/S2468-1253(19)30178-5. View

Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y . TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023; 109(5):1222-1230. PMC: 10389515. DOI: 10.1097/JS9.0000000000000256. View

Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L . Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Front Immunol. 2022; 13:848387. PMC: 8921060. DOI: 10.3389/fimmu.2022.848387. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S . Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021; 10(3):181-223. PMC: 8237791. DOI: 10.1159/000514174. View

10.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

11.

Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C . Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2022; 41(1):117-127. DOI: 10.1200/JCO.22.00392. View

12.

. [Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi. 2019; 27(3):172-181. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.003. View

13.

Lyu N, Wang X, Li J, Lai J, Chen Q, Li S . Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2021; 40(5):468-480. DOI: 10.1200/JCO.21.01963. View

14.

Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T . Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis. Radiat Oncol. 2018; 13(1):188. PMC: 6157064. DOI: 10.1186/s13014-018-1136-5. View

15.

Liu Y, Huang W, He M, Lian H, Guo Y, Huang J . Efficacy and Safety of CalliSpheres Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients. Oncol Res. 2018; 27(5):565-573. PMC: 7848450. DOI: 10.3727/096504018X15313896322888. View

16.

Zheng K, Zhu X, Fu S, Cao G, Li W, Xu L . Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology. 2022; 303(2):455-464. DOI: 10.1148/radiol.211545. View

17.

Ding X, Sun W, Li W, Shen Y, Guo X, Teng Y . Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. Cancer. 2021; 127(20):3782-3793. DOI: 10.1002/cncr.33677. View

18.

Guo Y, Wu J, Liang L, Zhu K, Zhou J, Lin L . Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study. Cancer Imaging. 2023; 23(1):91. PMC: 10518921. DOI: 10.1186/s40644-023-00604-4. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View